Cogent Biosciences, Inc. (COGT)
NASDAQ:COGT
Want to see COGT full AI Analyst Report?
Top Page
Cogent Biosciences
(NASDAQ:COGT)
Select Model
Select Model
Rating:45Neutral
Price Target:
$37.00
▼(-0.67% Downside)
Action:Reiterated
Date:06/12/26
The score is weighed down primarily by weak financial performance (no revenue, widening losses, and heavy cash burn) and bearish technical signals (below key moving averages with negative MACD). Valuation support is limited due to negative earnings and no dividend, while governance-related corporate events add a modest positive offset.
Positive Factors
Balance sheet cushion
Sizable equity relative to assets provides a durable financial cushion that supports continued R&D spending and operations over the medium term. This reduces the immediacy of financing pressure, giving management time to advance clinical programs before needing dilutive capital.
Negative Factors
No revenue, widening net losses
Persistent absence of revenue combined with accelerating net losses is a durable fundamental weakness: it reflects pre-commercial status with growing cash requirements. Over the next several months, this trend increases financing dependency and heightens dilution risk if clinical progress lags.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance sheet cushion
Sizable equity relative to assets provides a durable financial cushion that supports continued R&D spending and operations over the medium term. This reduces the immediacy of financing pressure, giving management time to advance clinical programs before needing dilutive capital.
Read all positive factors
Cogent Biosciences (COGT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$6.20B
Dividend YieldN/A
Average Volume (3M)2.19M
Price to Earnings (P/E)―
Beta (1Y)1.02
Revenue GrowthN/A
EPS Growth0.01%
CountryUS
Employees205
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-3.08
Shares Outstanding170,868,010
10 Day Avg. Volume2,313,315
30 Day Avg. Volume2,193,920
Financial Highlights & Ratios
PEG Ratio-3.81
Price to Book (P/B)3.77
Price to Sales (P/S)0.00
P/FCF Ratio-9.03
Enterprise Value/Market Cap0.93
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.65K
Enterprise Value/Ebitda-16.41
Forecast
1Y Price Target
$52.43Price Target Upside40.75% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-2.25
Revenue Forecast (FY)$10.85M
Cogent Biosciences Business Overview & Revenue Model
Company Description
Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered...
How the Company Makes Money
null...
Cogent Biosciences Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
55
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -3.49M | -4.62M | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -350.48M | -321.26M | -251.51M | -188.82M | -130.37M | -70.28M |
| Net Income | -354.30M | -328.94M | -255.86M | -192.41M | -140.24M | -72.27M |
Balance Sheet | ||||||
| Total Assets | 903.01M | 937.61M | 327.90M | 313.44M | 300.81M | 232.09M |
| Cash, Cash Equivalents and Short-Term Investments | 866.38M | 900.76M | 287.08M | 265.71M | 259.28M | 219.68M |
| Total Debt | 238.65M | 253.15M | 17.47M | 18.85M | 19.65M | 3.15M |
| Total Liabilities | 295.31M | 301.24M | 71.61M | 55.63M | 45.08M | 17.91M |
| Stockholders Equity | 607.69M | 636.37M | 256.29M | 257.80M | 255.74M | 214.18M |
Cash Flow | ||||||
| Free Cash Flow | -286.27M | -266.00M | -208.36M | -156.42M | -125.50M | -60.48M |
| Operating Cash Flow | -284.82M | -264.44M | -207.79M | -153.62M | -118.64M | -58.76M |
| Investing Cash Flow | -505.36M | -399.53M | 38.28M | -97.82M | -124.72M | -1.72M |
| Financing Cash Flow | 905.80M | 878.23M | 214.45M | 163.54M | 163.56M | 37.98M |
Cogent Biosciences Technical Analysis
Positive
37.25
Price Trends
34.54
Positive
35.63
Positive
31.44
Positive
Market Momentum
0.46
Negative
68.35
Neutral
90.71
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For COGT, the sentiment is Positive. The current price of 37.25 is above the 20-day moving average (MA) of 33.64, above the 50-day MA of 34.54, and above the 200-day MA of 31.44, indicating a bullish trend. The MACD of 0.46 indicates Negative momentum. The RSI at 68.35 is Neutral, neither overbought nor oversold. The STOCH value of 90.71 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for COGT.
Cogent Biosciences Risk Analysis
Cogent Biosciences disclosed 61 risk factors in its most recent earnings report. Cogent Biosciences reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Cogent Biosciences Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | $1.98B | 13.67 | 17.19% | ― | 20.71% | -5.53% | |
65 Neutral | $3.32B | -22.96 | -13.96% | ― | 3118.14% | 55.95% | |
61 Neutral | $1.48B | -80.10 | -4.83% | ― | 23.64% | -29.23% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $2.69B | -10.60 | -36.95% | ― | ― | -68.57% | |
48 Neutral | $3.42B | -52.97 | -5.89% | ― | 157.97% | 86.11% | |
45 Neutral | $6.20B | -12.19 | -83.29% | ― | ― | 0.01% |
* Healthcare Sector Average
COGT
Cogent Biosciences
38.01
30.68
418.55%
IDYA
IDEAYA Biosciences
36.29
14.00
62.81%
BEAM
Beam Therapeutics
33.93
16.79
97.96%
IRON
Disc Medicine
70.16
16.03
29.61%
HRMY
Harmony Biosciences Holdings
34.13
2.27
7.12%
IMCR
Immunocore Holdings
30.54
-1.48
-4.62%
Cogent Biosciences Corporate Events
Executive/Board ChangesShareholder Meetings
Cogent Biosciences Shareholders Back Board, Governance Proposals
Positive
Jun 11, 2026
At its recent Annual Meeting, Cogent Biosciences shareholders elected all three director nominees, Chris Cain, Ph.D., Arlene Morris and Todd Shegog, reflecting broad investor support for the company’s current leadership and strategic directi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.